| Literature DB >> 28091735 |
Shenglin Liu1, Qian Zhang2, Dongli Huang3, Wenli Zhang2, Fengluan Zhong2, Jia Feng2, Xueru Chen2, Qingxiang Meng2, Xiaofan Chen1, Wei Zhang4, Hongyu Zhang5.
Abstract
Epstein-Barr virus (EBV) primary infection is usually asymptomatic, but it sometimes progresses to infectious mononucleosis (IM). Occasionally, some people develop chronic active EBV infection (CAEBV) with underlying immunodeficiency, which belongs to a continuous spectrum of EBV-associated lymphoproliferative disorders (EBV+ LPD) with heterogeneous clinical presentations and high mortality. It has been well established that T cell-mediated immune response plays a critical role in the disease evolution of EBV infection. Recently, high-throughput sequencing of the hypervariable complementarity-determining region 3 (CDR3) segments of the T cell receptor (T cell receptor β (TCRβ)) has emerged as a sensitive approach to assess the T cell repertoire. In this study, we fully characterized the diversity of peripheral blood TCRβ repertoire in IM (n = 6) and CAEBV patients (n = 5) and EBV-seropositive controls (n = 5). Compared with the healthy EBV-seropositive controls, both IM and CAEBV patients demonstrate a significant decrease in peripheral blood TCRβ repertoire diversity, basically, including narrowed repertoire breadth, highly expanded clones, and skewed CDR3 length distribution. However, there is no significant difference between IM and CAEBV patients. Furthermore, we observed some disease-related preferences in TRBV/TRBJ usage and combinations, as well as lots of T cell clones shared by different groups (unique or overlapped) involved in public T cell responses, which provide more detailed insights into the divergent disease evolution.Entities:
Keywords: Chronic active EBV infection (CAEBV); Epstein-Barr virus (EBV); Infectious mononucleosis (IM); T cell receptor (TCRβ) repertoire complementarity-determining region 3 (CDR3)
Mesh:
Substances:
Year: 2017 PMID: 28091735 DOI: 10.1007/s00277-016-2911-8
Source DB: PubMed Journal: Ann Hematol ISSN: 0939-5555 Impact factor: 3.673